392 related articles for article (PubMed ID: 36348391)
1. Learn from antibody-drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy.
Wu M; Huang W; Yang N; Liu Y
Exp Hematol Oncol; 2022 Nov; 11(1):93. PubMed ID: 36348391
[TBL] [Abstract][Full Text] [Related]
2. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
[TBL] [Abstract][Full Text] [Related]
3. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?
Fu C; Yu L; Miao Y; Liu X; Yu Z; Wei M
Acta Pharm Sin B; 2023 Feb; 13(2):498-516. PubMed ID: 36873165
[TBL] [Abstract][Full Text] [Related]
4. Peptide Drug Conjugates and Their Role in Cancer Therapy.
Heh E; Allen J; Ramirez F; Lovasz D; Fernandez L; Hogg T; Riva H; Holland N; Chacon J
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614268
[TBL] [Abstract][Full Text] [Related]
5. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
[TBL] [Abstract][Full Text] [Related]
6. Targeted drug delivery for cancer therapy: the other side of antibodies.
Firer MA; Gellerman G
J Hematol Oncol; 2012 Nov; 5():70. PubMed ID: 23140144
[TBL] [Abstract][Full Text] [Related]
7. Construction of homogeneous antibody-drug conjugates using site-selective protein chemistry.
Akkapeddi P; Azizi SA; Freedy AM; Cal PMSD; Gois PMP; Bernardes GJL
Chem Sci; 2016 May; 7(5):2954-2963. PubMed ID: 29997785
[TBL] [Abstract][Full Text] [Related]
8. Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy.
Lindberg J; Nilvebrant J; Nygren PÅ; Lehmann F
Molecules; 2021 Oct; 26(19):. PubMed ID: 34641586
[TBL] [Abstract][Full Text] [Related]
9. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
10. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates Containing Payloads from Marine Origin.
Cheng-Sánchez I; Moya-Utrera F; Porras-Alcalá C; López-Romero JM; Sarabia F
Mar Drugs; 2022 Jul; 20(8):. PubMed ID: 36005497
[TBL] [Abstract][Full Text] [Related]
12. Introduction to Antibody-Drug Conjugates.
Pettinato MC
Antibodies (Basel); 2021 Oct; 10(4):. PubMed ID: 34842621
[TBL] [Abstract][Full Text] [Related]
13. Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma.
Jagadeesh D; Smith MR
Curr Treat Options Oncol; 2016 Oct; 17(10):55. PubMed ID: 27544507
[TBL] [Abstract][Full Text] [Related]
14. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
Zhang L; Fang Y; Kopeček J; Yang J
Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
[TBL] [Abstract][Full Text] [Related]
15. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel.
Wang L; Chen H; Wang F; Zhang X
Expert Opin Drug Deliv; 2022 Feb; 19(2):147-161. PubMed ID: 35130795
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers.
Peng H
Antib Ther; 2021 Oct; 4(4):222-227. PubMed ID: 34805745
[TBL] [Abstract][Full Text] [Related]
17. Advances in targeted therapy for pancreatic cancer.
Xing L; Lv L; Ren J; Yu H; Zhao X; Kong X; Xiang H; Tao X; Dong D
Biomed Pharmacother; 2023 Dec; 168():115717. PubMed ID: 37862965
[TBL] [Abstract][Full Text] [Related]
18. Potential of antibody-drug conjugates (ADCs) for cancer therapy.
Marei HE; Cenciarelli C; Hasan A
Cancer Cell Int; 2022 Aug; 22(1):255. PubMed ID: 35964048
[TBL] [Abstract][Full Text] [Related]
19. Trends in cancer-targeted antibody-drug conjugates.
Bidard FC; Trédan O
Target Oncol; 2014 Mar; 9(1):1-8. PubMed ID: 24221961
[TBL] [Abstract][Full Text] [Related]
20. Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates.
Tedeschini T; Campara B; Grigoletto A; Bellini M; Salvalaio M; Matsuno Y; Suzuki A; Yoshioka H; Pasut G
J Control Release; 2021 Sep; 337():431-447. PubMed ID: 34329685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
